T3D THERAPEUTICS
T3D Therapeutics is a developer of a novel drug therapy intended to stop or reverse the course of Alzheimer's disease. The company's drug is an orally-delivered once-a-day medicine that targets both the brain 'starvation' and neurodegeneration of Alzheimer's disease and helps in treating multiple manifestations of the disease, providing Alzheimer patients with a drug to potentially improve multiple defects and improve memory, motor function and cognition. T3D Therapeutics is based in Durham, North Carolina, and was founded in 2013.
T3D THERAPEUTICS
Social Links:
Industry:
Biotechnology Medical Therapeutics
Founded:
2013-01-01
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.t3dtherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
919-237-4897
Email Addresses:
[email protected]
Total Funding:
40.31 M USD
Technology used in webpage:
Euro Google Maps Sucuri Hosting
Similar Organizations
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
Current Advisors List
Current Employees Featured
Founder
Investors List
National Institute on Aging
National Institute on Aging investment in Series B - T3D Therapeutics
Official Site Inspections
http://www.t3dtherapeutics.com
- Host name: cloudproxy10006.sucuri.net
- IP address: 192.124.249.6
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "T3D Therapeutics"
About Us - T3D Therapeutics
A Transformational Approach to Treating Alzheimer’s Disease … and more. T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ …See details»
Management Team - T3D Therapeutics
(919) 237-4897 [email protected]. Home; About. Mission; Lead Product Candidate T3D-959; Management Team; Scientific Advisory Board; Board of Directors; Pipeline. Alzheimer’s …See details»
T3D Therapeutics, Inc. | LinkedIn
T3D Therapeutics, Inc. | 350 followers on LinkedIn. Developing a potentially disease-modifying, new drug treatment for Alzheimer’s and other neurodegenerative diseases. | T3D Therapeutics ...See details»
T3D Therapeutics - Crunchbase Company Profile
T3D Therapeutics is a developer of a novel drug therapy intended to stop or reverse the course of Alzheimer's disease. The company's drug is an orally-delivered once-a-day medicine that targets both the brain 'starvation' and …See details»
- Drug pipelines, Patents, Clinical trials - Synapse
For more information visit . CONTACT: John Didsbury, Ph.D., CEO T3D Therapeutics, Inc. 1-919-237-4897 Email: info (at) t3dtherapeutics (dot) com SOURCE T3D Therapeutics, Inc. ... The …See details»
T3D Therapeutics - Overview, News & Similar companies - ZoomInfo
T3D Therapeutics contact info: Phone number: (919) 237-4897 Website: www.t3dtherapeutics.com What does T3D Therapeutics do? T3D Therapeutics, Inc. was …See details»
T3D Therapeutics Company Profile - Office Locations ... - Craft
T3D Therapeutics $34.3 m in total funding,. See insights on T3D Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Mission - T3D Therapeutics
A Transformational Approach to Treating Alzheimer’s Disease … and more. T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ …See details»
T3D Therapeutics - PitchBook
T3D Therapeutics General Information Description. Developer of a novel drug therapy designed to offer a transformational approach that can stop or reverse the course of Alzheimer's disease.See details»
T3D Therapeutics, Inc.: T3D Therapeutics Announces First
Apr 20, 2021 RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / April 20, 2021 / T3D Therapeutics, Inc. (“T3D”), a clinical stage drug development company engaged in the …See details»
T3D Therapeutics Receives a Research Award from the Alzheimer's ...
Aug 27, 2020 The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. ... t3dtherapeutics (dot) com. SOURCE …See details»
T3D Therapeutics Selected to Present Topline Results from the …
Oct 3, 2023 T3D Therapeutics, Inc. ("T3D") a clinical stage drug development company engaged in the development of T3D-959, a new orally administered drug intended for the treatment of …See details»
T3D Therapeutics Selected to Present Topline Results from the …
Oct 3, 2023 RESEARCH TRIANGLE PARK, N.C., Oct. 3, 2023 /PRNewswire/ -- T3D Therapeutics, Inc. ("T3D") a clinical stage drug development company engaged in the …See details»
Contact Us - T3D Therapeutics
(919) 237-4897 [email protected]. Home; About. Mission; Lead Product Candidate T3D-959; Management Team; Scientific Advisory Board; Board of Directors; Pipeline. Alzheimer’s …See details»
T3D Therapeutics Closes $15M Financing to Advance Phase 2 …
Nov 5, 2019 T3D Therapeutics is now fully funded to initiate the Phase 2 PIONEER Study of T3D-959 in Mild-to-Moderate Alzheimer's Disease Patients. RESEARCH TRIANGLE PARK, …See details»
News + Events - T3D Therapeutics
Jul 31, 2024 (919) 237-4897 [email protected]. Home; About. Mission; Lead Product Candidate T3D-959; Management Team; Scientific Advisory Board; Board of Directors; …See details»
T3D Therapeutics Closes $15M Financing to Advance Phase 2 …
Nov 4, 2019 T3D Therapeutics Closes $15M Financing to Advance Phase 2 Development of T3D-959 in a New Approach to Treating Alzheimer's Disease. T3D Therapeutics is now fully …See details»
Pipeline - T3D Therapeutics
(919) 237-4897 [email protected]. Home; About. Mission; Lead Product Candidate T3D-959; Management Team; Scientific Advisory Board; Board of Directors; Pipeline. Alzheimer’s …See details»
T3D Therapeutics Announces Positive Top-Line Results from the …
Nov 3, 2023 RESEARCH TRIANGLE PARK, N.C., Nov. 3, 2023 /PRNewswire/ -- T3D Therapeutics presented top-line results from its Phase 2 PIONEER study at the 16 th …See details»